The Primary
Care Companionfor CNS Disorders

Schizophrenia/Schizoaffective Disorders

Letter to the Editor December 15, 2008

Vigilance Needed in Recognizing Behavior Changes in Patients Taking Statins

Mark R. Goldstein, M.D. ; Luca Mascitelli, M.D. ; Francesca Pezzetta, M.D.

Prim Care Companion J Clin Psychiatry 2008;10(6):482-482

Article Abstract

Letter to the Editor

Vigilance Needed in Recognizing Behavior Changes in Patients Taking Statins Letters to the Editor

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 27 • 2025 • Number 1

Read the Current Issue

Case Report

Thyrotoxic Psychosis in Graves’ Disease

Rounds in the General Hospital

Psychosis-Related PTSD

Case Report

Factitious Disorder in the Context of Abuse in an Adolescent

Rounds in the General Hospital

Wishing That Your Patient Would Die: Reasons and Reactions

Case Report

Frontal Lobe Syndrome Unveils an Unexpected Diagnosis

Case Report

Low-Dose Clozapine in Schizophrenia With Aggression

View current Issue

Letter to the Editor

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...

Xintong Mu , Hiroyoshi Takeuchi

Letter to the Editor

Asenapine, Aggression, and Affinity

September 28, 2022

Dr El-Mallakh comments on a recent study by Citrome et al and discusses his group’s research on antiaggression effects of clozapine.

Rif S. El-Mallakh

Letter to the Editor

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

August 3, 2022

This letter comments on methodological aspects of a recent study by Cohen et al.

Florian Naudet , André Gillibert , Barbara Mintzes , et al

Vigilance Needed in Recognizing Behavior Changes in Patients Taking Statins

Read the Current Issue

Thyrotoxic Psychosis in Graves’ Disease

Psychosis-Related PTSD

Factitious Disorder in the Context of Abuse in an Adolescent

Wishing That Your Patient Would Die: Reasons and Reactions

Frontal Lobe Syndrome Unveils an Unexpected Diagnosis

Low-Dose Clozapine in Schizophrenia With Aggression

ELSEWHERE:

FOLLOW US:

Vigilance Needed in Recognizing Behavior Changes in Patients Taking Statins

Read the Current Issue

Thyrotoxic Psychosis in Graves’ Disease

Psychosis-Related PTSD

Factitious Disorder in the Context of Abuse in an Adolescent

Wishing That Your Patient Would Die: Reasons and Reactions

Frontal Lobe Syndrome Unveils an Unexpected Diagnosis

Low-Dose Clozapine in Schizophrenia With Aggression

Related Articles

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

Asenapine, Aggression, and Affinity

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles